Encompass More Asset Management Purchases 1,128 Shares of Novo Nordisk A/S (NYSE:NVO)

Encompass More Asset Management increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 49.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,397 shares of the company’s stock after acquiring an additional 1,128 shares during the period. Encompass More Asset Management’s holdings in Novo Nordisk A/S were worth $292,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the third quarter worth about $42,000. Carolina Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $48,000. Finally, M&R Capital Management Inc. boosted its stake in shares of Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $87.94 on Friday. The company has a market capitalization of $394.65 billion, a price-to-earnings ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The stock has a fifty day simple moving average of $95.62 and a 200 day simple moving average of $115.55.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.